Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors
Clinical Epidemiology · 2026-11 · Volume 18 · 1-12
DOI: 10.2147/clep.s630762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Epidemiology, 2026-11. Verfasst von Max Shen und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The validity of ILD coding in US claims data among patients with cancer remains unclear.
Methods
We conducted a study to test the validity of ILD coding in claims data in patients with lung, breast, ovarian, endometrial, cervical, or colorectal cancer. We used electronic health record (EHR) data from the Mass General Brigham Health Care System linked with Medicare, Medicaid, and commercial claims data from 01/01/2017 to 12/31/2024. The base algorithm required two ICD-10-CM codes for ILD, each 7 to 180 days apart. Several nested algorithms additionally requiring ILD coding by a pulmonologist, ILD-relevant procedure, excluding autoimmune diseases, and requiring chemo/immunotherapy treatment were defined. The positive predictive values (PPVs) of each claims-based algorithm were calculated against the reference standard established through chart review by pulmonologists.
Results
The cohort consisted of 360 patients. PPV of the base algorithm was 59% (95% confidence interval: 53%– 64%). The algorithm additionally requiring ILD-relevant procedure with chemo- or immunotherapy administration and excluding those with autoimmune conditions was 64% (57%– 71%). The PPV of base algorithm among patients with colorectal cancer was the lowest - 38% (24%– 52%). The PPVs improved meaningfully when the index diagnosis of ILD was coded by a pulmonologist, ranging from 78– 88% across different algorithms.
Conclusion
We found that, in patients diagnosed with lung, breast, gynecologic, or colorectal cancer, claims-based ILD diagnoses demonstrated moderate to low alignment with a reference standard by expert chart review. It can be improved when ILD is coded by a pulmonologist, though at the cost of substantially fewer cases of ILD identified. Keywords: interstitial lung disease, breast cancer, lung cancer, ovarian cancer, validation, ICD-10
Zitieren
APA
Shen, M., Wang, S., Schneeweiss, S., McNeill, A. M., Calip, G. S., Yue, S., Clarke, M. A., Liu, J., Nathwani, N., Anand, P., & Lin, K. J. (2026). Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors. Clinical Epidemiology, Volume 18, 1-12. https://doi.org/10.2147/clep.s630762
Vancouver
Shen M, Wang S, Schneeweiss S, McNeill AM, Calip GS, Yue S, et al. Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors. Clinical Epidemiology. 2026;Volume 18:1-12. doi:10.2147/clep.s630762
BibTeX
@article{Shen2026,
author = {Shen, Max and Wang, Stephanie and Schneeweiss, Sebastian and McNeill, Ann Marie and Calip, Gregory S and Yue, Susan and Clarke, Megan A and Liu, Jun and Nathwani, Neesha and Anand, Priyanka and Lin, Kueiyu Joshua},
title = {Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors},
journal = {Clinical Epidemiology},
year = {2026},
volume = {Volume 18},
pages = {1--12},
doi = {10.2147/clep.s630762}
}
EUVIMED